[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1193
6. Gebauer K, Shumack S, Cowen PS: Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol; 2009 Oct;161(4):897-903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
  • BACKGROUND: Clinical studies in cutaneous conditions other than actinic keratosis (AK) have revealed that the safety and efficacy profile of imiquimod is influenced by dosing frequency.
  • OBJECTIVES: To evaluate dosing frequency response of imiquimod 5% for treatment of AK.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Hand Dermatoses / drug therapy. Keratosis, Actinic / drug therapy. Precancerous Conditions / drug therapy

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19545297.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


7. Martin G: The impact of the current United States guidelines on the management of actinic keratosis: is it time for an update? J Clin Aesthet Dermatol; 2010 Nov;3(11):20-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of the current United States guidelines on the management of actinic keratosis: is it time for an update?
  • Actinic keratosis is one of the most common diagnoses made by dermatologists.
  • Many experts recommend treating all actinic keratoses because of their potential to progress to invasive squamous cell carcinoma.
  • Physicians have a large armamentarium of actinic keratosis treatment modalities available to them, including destructive therapies, such as cryotherapy, curettage and electrodessication, chemical peels, photodynamic therapy, and topical therapies, including 5-fluorouracil, imiquimod, and diclofenac.
  • This abundance of treatment options prompted development of several actinic keratosis management guidelines.
  • While there are benefits and potential limitations to developing an updated set of United States-based guidelines, there is a clearly defined need for a unified, comprehensive, evidence-based guideline approach to actinic keratosis treatment that balances the need to tailor long-term management of the disease to the needs of the individual patient.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103312.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2989810
  •  go-up   go-down


8. Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Ostano P, Dummer R, Brissette JL, Dotto GP: A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest; 2009 Oct;119(10):3127-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.
  • Seborrheic keratoses (SKs) are common, benign epithelial tumors of the skin that do not, or very rarely, progress into malignancy, for reasons that are not understood.
  • Knockdown of FOXN1 expression in primary human keratinocytes cooperated with oncogenic RAS in the induction of SCC-like tumors, whereas increased FOXN1 expression triggered the SCC cells to shift to a benign SK-like tumor phenotype, which included increased FGFR3 expression.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Apr 15;20(8):1028-42 [16618808.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2201-2207 [16841094.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2404-7 [16778799.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3465-71 [16849642.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):60-6 [16807070.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1268-78 [17304214.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3732-42 [17353266.001]
  • [Cites] J Invest Dermatol. 2007 Aug;127(8):1883-5 [17392824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13450-4 [17673550.001]
  • [Cites] Cell. 2007 Sep 7;130(5):932-42 [17803914.001]
  • [Cites] Differentiation. 2007 Oct;75(8):694-701 [17459087.001]
  • [Cites] World J Urol. 2007 Dec;25(6):581-93 [17912529.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):342-6 [18223206.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):1-7 [18231634.001]
  • [Cites] Curr Urol Rep. 2008 Jan;9(1):55-61 [18366975.001]
  • [Cites] EMBO J. 2008 Apr 23;27(8):1243-54 [18388864.001]
  • [Cites] Nat Cell Biol. 2008 Aug;10(8):902-11 [18604200.001]
  • [Cites] Curr Opin Oncol. 2006 May;18(3):228-33 [16552233.001]
  • [Cites] Adv Dermatol. 1999;14:307-57 [10643503.001]
  • [Cites] J Bone Miner Res. 2000 Jan;15(1):155-65 [10646125.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] J Invest Dermatol. 2001 Apr;116(4):506-10 [11286615.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] J Korean Med Sci. 2001 Oct;16(5):619-22 [11641533.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):303-9 [11841548.001]
  • [Cites] Cell Signal. 2002 Jul;14(7):585-93 [11955951.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):288-93 [12042702.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1105-14 [12357246.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):444-51 [12778134.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):865-77 [12791271.001]
  • [Cites] Blood. 2003 Jul 15;102(2):772-3 [12835230.001]
  • [Cites] CA Cancer J Clin. 2003 Sep-Oct;53(5):292-302 [14570228.001]
  • [Cites] Nat Immunol. 2003 Nov;4(11):1128-35 [14528302.001]
  • [Cites] Am Fam Physician. 2003 Nov 15;68(10):1963-8 [14655805.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4555-62 [15231666.001]
  • [Cites] J Cell Sci. 2004 Aug 15;117(Pt 18):4157-68 [15316080.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6035-40 [15342384.001]
  • [Cites] Cancer Res. 1981 May;41(5):1657-63 [7214336.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1187-97 [2578876.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] Mol Carcinog. 1994 Sep;11(1):19-28 [7916986.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):103-7 [7969402.001]
  • [Cites] Genomics. 1995 Aug 10;28(3):549-59 [7490093.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15292-7 [8663044.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2212-21 [8804315.001]
  • [Cites] Science. 1997 Jan 17;275(5298):400-2 [8994040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3842-7 [9108066.001]
  • [Cites] Immunogenetics. 1997;46(6):509-15 [9321431.001]
  • [Cites] Trends Biochem Sci. 1998 Feb;23(2):59-62 [9538690.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] Med Clin North Am. 1998 Nov;82(6):1285-307, v-vi [9889749.001]
  • [Cites] Genes Dev. 1999 Mar 1;13(5):607-19 [10072388.001]
  • [Cites] Dev Biol. 1999 Apr 15;208(2):362-74 [10191051.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):473-4 [10206641.001]
  • [Cites] Hum Mol Genet. 2005 May 1;14(9):1153-60 [15772091.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):867-76 [15854024.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Dev Cell. 2005 May;8(5):665-76 [15866158.001]
  • [ErratumIn] J Clin Invest. 2010 Feb;120(2):6455. Pazin, Mike [corrected to Pazin, Michael J]
  • (PMID = 19729838.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR39190; United States / NCI NIH HHS / CA / CA16038; United States / NIAMS NIH HHS / AR / R01 AR045284; United States / NIAMS NIH HHS / AR / AR054856; United States / NCI NIH HHS / CA / R01 CA073796; United States / Intramural NIH HHS / / ZIA AG000378-03; United States / NIAMS NIH HHS / AR / AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR039190; United States / NIAMS NIH HHS / AR / R01 AR055218-02; United States / NCI NIH HHS / CA / P01 CA016038; United States / NCI NIH HHS / CA / CA73796; United States / NIAMS NIH HHS / AR / AR055218-02; United States / NIAMS NIH HHS / AR / AR045284; United States / NIAMS NIH HHS / AR / R01 AR055218; United States / NIAMS NIH HHS / AR / R01 AR054856
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Whn protein; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


9. Schmutz JL, Barbaud A, Trechot P: [Erosive pustulosis on the scalp following dynamic phototherapy]. Ann Dermatol Venereol; 2010 Jan;137(1):86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Aged, 80 and over. Aminolevulinic Acid / adverse effects. Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Female. Humans. Keratosis, Actinic / complications. Keratosis, Actinic / drug therapy. Laser Therapy / adverse effects. Photosensitizing Agents / adverse effects. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110080.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / delta-aminolevulinic acid methyl ester; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


10. Roewert-Huber J, Stockfleth E, Kerl H: Pathology and pathobiology of actinic (solar) keratosis - an update. Br J Dermatol; 2007 Dec;157 Suppl 2:18-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology and pathobiology of actinic (solar) keratosis - an update.
  • Actinic keratosis is a UV light-induced lesion and develops mostly in fair-skinned patients being susceptible to solar damage.
  • The term actinic keratosis (AK) describes clinically ill-defined reddish to reddish-brown scaly lesions on erythematous base in areas damaged severely by sunlight.
  • Actinic keratoses (AKs) have been recognized as precursor of cancer or of precancerous lesions in the past but today they are considered as an early in situ squamous cell carcinoma (1,2) and are categorized in several classifications with subdivisions into three grades depending on the amount of atypical keratinocytes in the epidermis.(3-6) The incidence of development of AK in caucasians increases with age, proximity to the equator and outdoor occupation.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis / pathology. Neoplasms, Radiation-Induced / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067626.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


11. Feller L, Khammissa RA, Wood NH, Jadwat Y, Meyerov R, Lemmer J: Sunlight (actinic) keratosis: an update. J Prev Med Hyg; 2009 Dec;50(4):217-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunlight (actinic) keratosis: an update.
  • [MeSH-major] Keratosis, Actinic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20812516.001).
  • [ISSN] 1121-2233
  • [Journal-full-title] Journal of preventive medicine and hygiene
  • [ISO-abbreviation] J Prev Med Hyg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 28
  •  go-up   go-down


12. Kavak A, Parlak AH, Yesildal N, Aydogan I, Anul H: Preliminary study among truck drivers in Turkey: effects of ultraviolet light on some skin entities. J Dermatol; 2008 Mar;35(3):146-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatological entities such as actinic keratosis, solar lentigo, seborrheic keratosis, melanocytic nevus, spider angioma, ephelid, basal cell carcinoma (BCC), squamous cell carcinoma, and melanoma were compared to driver and right sides.
  • Seborrheic keratosis and lentigo solaris were found to be increased on the driver side of the face (P = 0.00) and ear (P = 0.013), respectively.
  • Statistically significant increases of lesions on the driver side were determined according to the subgroups: melanocytic nevi were found to be increased on the driver side in A1 (P = 0.00), A2 (P = 0.00), O2 (P = 0.00), S1 (P = 0.00) and S2 (P = 0.006) groups; actinic keratoses were found to be significantly increased on the driver side in A2 and O2 groups (P = 0.03 for both).

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346257.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Campbell SM, Morton CA, Alyahya R, Horton S, Pye A, Curnow A: Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol; 2008 Aug;159(2):387-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evidence-based guidelines support the efficacy of PDT using topical 5-aminolaevulinic acid (ALA-PDT) in actinic keratoses, Bowen disease and basal cell carcinoma (BCC).

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2009 Jul;161(1):215-6 [19438852.001]
  • (PMID = 18544077.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron Chelating Agents; 0 / Photosensitizing Agents; 0 / Pyridones; 115900-75-9 / 1,2-diethyl-3-hydroxypyridin-4-one; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


1
Advertisement
4. de Gruijl FR: UV-induced immunosuppression in the balance. Photochem Photobiol; 2008 Jan-Feb;84(1):2-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Around 1980, experiments with hairless mice showed us that UV-induced actinic keratoses (AK) and ensuing skin carcinomas did not arise independently: the rate of occurrence in one skin area was increased considerably if AKs had already been induced separately in another distant skin area, i.e. a systemic effect.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18173695.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 97
  •  go-up   go-down


15. Leyral C, Beylot-Barry M, Vergier B, Begueret H, Dromer C, Doutre MS, Beylot C: [Cyclosporine-induced follicular eruption]. Ann Dermatol Venereol; 2008 Jan;135(1):58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis of cyclosporine-induced follicular eruption was adopted on the basis of the histological and microbiological findings.
  • DISCUSSION: Three similar cases were previously reported characterized by typical follicular changes different from those observed in hypertrichosis or pilar keratosis.

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342076.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


16. Garcia-Zuazaga J, Cooper KD, Baron ED: Photodynamic therapy in dermatology: current concepts in the treatment of skin cancer. Expert Rev Anticancer Ther; 2005 Oct;5(5):791-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy has been approved by the US Food and Drug Administration to treat actinic keratoses.
  • In Europe, photodynamic therapy is currently being used in the treatment of actinic keratoses and basal cell carcinoma.
  • Other off-label uses of photodynamic therapy have included cutaneous lesions of Bowen's disease, psoriasis, cutaneous T-cell lymphoma and acne.
  • [MeSH-minor] Aminolevulinic Acid / therapeutic use. Clinical Trials as Topic. Humans. Keratosis / drug therapy. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221049.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 46
  •  go-up   go-down


17. Goh MS, Magee J, Chong AH: Keratosis follicularis spinulosa decalvans and acne keloidalis nuchae. Australas J Dermatol; 2005 Nov;46(4):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratosis follicularis spinulosa decalvans and acne keloidalis nuchae.
  • Additionally, there was keratosis pilaris on the cheeks, eyebrows and thighs.
  • With clinical correlation, the diagnosis of keratosis follicularis spinulosa decalvans and concurrent acne keloidalis nuchae was made.
  • The association of keratosis follicularis spinulosa decalvans with acne keloidalis nuchae has not previously been described.
  • [MeSH-major] Acne Keloid / diagnosis. Acne Keloid / etiology. Darier Disease / complications. Darier Disease / diagnosis. Scalp Dermatoses / diagnosis. Scalp Dermatoses / etiology


18. Pirard D, Vereecken P, Mélot C, Heenen M: Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res; 2005 Nov;297(5):185-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies.
  • Three percent diclofenac in 2.5% hyaluronan gel (DHA) is approved by the Food and Drug Administration (FDA) in the treatment of actinic keratoses (AK).
  • DHA is effective compared to HAV in the treatment of AK.
  • Further studies should establish subgroup analyses according to sites and severity of the AK lesions in order to determine if more patients could be improved in restricted indications.
  • Biopsies, a longer follow-up evaluation, and comparisons with the other treatments of AK will also be helpful in the future to define the place of this treatment in the management of AK.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Diclofenac / administration & dosage. Hyaluronic Acid / administration & dosage. Keratosis / drug therapy

  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235081.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac; 27YG812J1I / Arachidonic Acid; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


19. Jeffries ML, Aleck KA, Bernert RA, Hansen RC: Eccrine squamous metaplasia and periadnexal granulomas: new cutaneous histopathologic findings in cardiofaciocutaneous syndrome. Pediatr Dermatol; 2010 May-Jun;27(3):274-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiofaciocutaneous syndrome is a rare genetic disorder characterized by dysmorphic facial features and neurologic, cardiac, ophthalmologic, and dermatologic findings.
  • Previously reported skin and hair findings in cardiofaciocutaneous syndrome include sparse, slow-growing curly hair, atopic dermatitis, ichthyosis, follicular hyperkeratosis, and keratosis pilaris.

  • Genetic Alliance. consumer health - Cardiofaciocutaneous Syndrome.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. Clobetasol .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804494.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Pregnadienediols; 04201GDN4R / Mometasone Furoate; 7KYV510875 / pimecrolimus; ADN79D536H / Clobetasol; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; WI4X0X7BPJ / Hydrocortisone; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


20. El Kabbaj N, Dereure O, Guillot B: [Erosive pustulosis of the scalp: 3 cases]. Ann Dermatol Venereol; 2005 May;132(5):475-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBSERVATIONS: Two patients (66 and 87 years old) presented with crusted and erosive pustules of the scalp following surgical removal of actinic keratosis and total skin graft.
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Alopecia / etiology. Gluconates / therapeutic use. Humans. Keratosis / surgery. Male. Skin Transplantation. Steroids / therapeutic use. Treatment Outcome. Zinc / therapeutic use

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988362.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Gluconates; 0 / Steroids; J41CSQ7QDS / Zinc
  •  go-up   go-down


21. Ooi T, Barnetson RS, Zhuang L, McKane S, Lee JH, Slade HB, Halliday GM: Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol; 2006 Jan;154(1):72-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial.
  • BACKGROUND: Imiquimod 5% cream is a topically applied immune response modifier that has been shown to give effective treatment of actinic keratosis (AK).
  • OBJECTIVES: To determine the nature of cellular infiltrates induced by the application of imiquimod to AK lesions and to study cells involved in the cutaneous immune response.
  • Each patient had punch biopsies of two distinct AK lesions: a lesion was biopsied before treatment to obtain baseline biomarker levels, and a different lesion was biopsied after 2 weeks of treatment.
  • Complete clearance of all treated AK lesions was achieved in five of 11 (45%) imiquimod patients and in none of six vehicle patients.
  • [MeSH-major] Aminoquinolines / therapeutic use. Dendritic Cells / drug effects. Keratosis / drug therapy. Photosensitivity Disorders / drug therapy. T-Lymphocyte Subsets / drug effects

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403097.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Biomarkers; 0 / Interferon Inducers; 99011-02-6 / imiquimod
  •  go-up   go-down


22. Rossi R, Mori M, Lotti T: Actinic keratosis. Int J Dermatol; 2007 Sep;46(9):895-904
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratosis.
  • [MeSH-major] Keratosis. Precancerous Conditions. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Dermatologic Agents / therapeutic use. Diagnosis, Differential. Humans. Male. Neoplasms, Squamous Cell / etiology. Neoplasms, Squamous Cell / pathology. Skin / pathology. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822489.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Dermatologic Agents
  • [Number-of-references] 51
  •  go-up   go-down


23. Brown SJ, Relton CL, Liao H, Zhao Y, Sandilands A, McLean WH, Cordell HJ, Reynolds NJ: Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. Br J Dermatol; 2009 Oct;161(4):884-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Summating skin features known to be associated with FLG null mutations (ichthyosis, keratosis pilaris, palmar hyperlinearity and flexural eczema) showed a penetrance of 100% in children with two FLG mutations, 87.8% in children with one FLG mutation and 46.5% in wild-type individuals (P < 0.0001, Fisher exact test).
  • [MeSH-minor] Child. Dermatitis, Atopic / genetics. Female. Genetic Predisposition to Disease / genetics. Humans. Ichthyosis Vulgaris / genetics. Male. Phenotype. Prospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Eczema.
  • MedlinePlus Health Information. consumer health - Eczema.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):901-10 [14638864.001]
  • [Cites] Br Med J. 1966 Apr 16;1(5493):947-50 [20790920.001]
  • [Cites] J Allergy Clin Immunol. 2004 May;113(5):832-6 [15131563.001]
  • [Cites] Br J Dermatol. 1985 Jun;112(6):679-85 [4005167.001]
  • [Cites] Mol Cell Biol. 1993 Jan;13(1):613-25 [8417356.001]
  • [Cites] Acta Derm Venereol. 1999 Sep;79(5):356-9 [10494710.001]
  • [Cites] Hum Mol Genet. 2005 Jan 15;14(2):335-46 [15590704.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):56-65 [15619623.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):328-40 [15803139.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):1071-4 [15854050.001]
  • [Cites] Exp Dermatol. 2005 Oct;14(10):719-26 [16176279.001]
  • [Cites] Arch Dermatol Res. 2005 Dec;297(6):235-41 [16261374.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):337-42 [16444271.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):441-6 [16550169.001]
  • [Cites] J Invest Dermatol. 2006 Aug;126(8):1770-5 [16810297.001]
  • [Cites] J Invest Dermatol. 2007 Mar;127(3):564-7 [16990802.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):173-82 [17403930.001]
  • [Cites] Nat Genet. 2007 May;39(5):650-4 [17417636.001]
  • [Cites] Nat Cell Biol. 2007 Jun;9(6):666-74 [17515931.001]
  • [Cites] J Invest Dermatol. 2007 Jul;127(7):1667-72 [17301831.001]
  • [Cites] J Allergy Clin Immunol. 2007 Jul;120(1):150-5 [17512043.001]
  • [Cites] Br J Dermatol. 2007 Oct;157(4):645-8 [17714568.001]
  • [Cites] Acta Derm Venereol. 2007;87(6):499-505 [17989887.001]
  • [Cites] Pharmacogenomics. 2008 Apr;9(4):399-413 [18384254.001]
  • [Cites] J Allergy Clin Immunol. 2008 Apr;121(4):940-46.e3 [18313126.001]
  • [Cites] J Allergy Clin Immunol. 2008 Apr;121(4):872-7.e9 [18325573.001]
  • [Cites] J Allergy Clin Immunol. 2008 May;121(5):1294-5; author reply 1295-6 [18395783.001]
  • [Cites] J Allergy Clin Immunol. 2008 May;121(5):1203-1209.e1 [18396323.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1430-5 [18049447.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1591-4 [18094728.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1436-41 [18200065.001]
  • [Cites] J Invest Dermatol. 2008 Jul;128(7):1669-75 [18239616.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2117-9 [18305568.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2008 Oct;8(5):406-10 [18769192.001]
  • [Cites] J Allergy Clin Immunol. 2008 Oct;122(4):689-93 [18774165.001]
  • [Cites] J Invest Dermatol. 2009 Mar;129(3):543-52 [19209157.001]
  • [Cites] J Invest Dermatol. 2009 Apr;129(4):1042-5 [18987673.001]
  • [Cites] Dermatol Ther. 2004;17 Suppl 1:43-8 [14728698.001]
  • (PMID = 19681860.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 074524; United Kingdom / Medical Research Council / / G0700314; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / filaggrin
  • [Other-IDs] NLM/ PMC2883069
  •  go-up   go-down


24. Butani AK, Arbesfeld DM, Schwartz RA: Premalignant and early squamous cell carcinoma. Clin Plast Surg; 2005 Apr;32(2):223-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Actinic keratosis (AK) is a common sun-induced precancerous neoplasm confined to the epidermis.
  • The AK is the initial manifestation of a continuum of clinical and histologic abnormalities that progresses to invasive squamous cell carcinoma (SCC).
  • Bowen's disease, also known as squamous cell carcinoma in situ, represents early SCC confined to the epidermis.
  • Like SCCs, the vast majority of AKs and Bowen's disease lesions are asymptomatic.
  • Each AK and suspicious lesion should be treated before it progresses to invasive SCC.
  • [MeSH-minor] Bowen's Disease / diagnosis. Bowen's Disease / therapy. Humans. Keratosis / diagnosis. Keratosis / therapy


25. Kim C, Fangman W: Keratosis follicularis (Darier-White disease), with an unusual palmoplantar keratoderma. Dermatol Online J; 2007;13(1):7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratosis follicularis (Darier-White disease), with an unusual palmoplantar keratoderma.
  • A diagnosis of keratosis follicularis was made, which has been treated with isotretinoin.
  • Palmoplantar lesions of keratosis follicularis have been described as discrete, punctate keratoses, hyperkeratotic papules, small pits, or keratin-filled depressions.
  • This patient has an unusual palmoplantar keratoderma in association with keratosis follicularis.
  • [MeSH-major] Darier Disease / complications. Keratoderma, Palmoplantar / etiology
  • [MeSH-minor] Administration, Oral. Adult. Biopsy. Diagnosis, Differential. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Genetic Predisposition to Disease. Humans. Isotretinoin / administration & dosage. Keratolytic Agents / administration & dosage. Ointment Bases / administration & dosage. Petrolatum / administration & dosage. Salicylic Acid / administration & dosage. Skin / pathology

  • Genetic Alliance. consumer health - Darier Disease.
  • Genetic Alliance. consumer health - Palmoplantar Keratoderma.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • Hazardous Substances Data Bank. SALICYLIC ACID .
  • Hazardous Substances Data Bank. PETROLATUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511940.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratolytic Agents; 0 / Ointment Bases; 8009-03-8 / Petrolatum; EH28UP18IF / Isotretinoin; O414PZ4LPZ / Salicylic Acid
  •  go-up   go-down


26. Pavlović MD, Milenković T, Dinić M, Misović M, Daković D, Todorović S, Daković Z, Zecevi RD, Doder R: The prevalence of cutaneous manifestations in young patients with type 1 diabetes. Diabetes Care; 2007 Aug;30(8):1964-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of the study was to assess the prevalence of cutaneous disorders and their relation to disease duration, metabolic control, and microvascular complications in children and adolescents with type 1 diabetes.
  • RESULTS: One hundred forty-two (68%) type 1 diabetic patients had at least one cutaneous disorder vs. 52 (26.5%) control subjects (P < 0.01).
  • Keratosis pilaris affected 12% of our patients vs. 1.5% of control subjects.
  • Significant association was also found between acquired ichthyosis and keratosis pilaris (1.53 [1.09-1.79]; P < 0.001).
  • CONCLUSIONS: Cutaneous manifestations are common in type 1 diabetic patients, and some of them, like acquired ichthyosis and keratosis pilaris, develop early in the course of the disease.
  • Diabetic hand and rubeosis faciei are related to disease duration.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519431.001).
  • [ISSN] 1935-5548
  • [Journal-full-title] Diabetes care
  • [ISO-abbreviation] Diabetes Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Lee WJ, Park GH, Lee MW, Choi JH, Moon KC, Koh JK: Keratosis follicularis and dermatomyositis: is there a common pathogenesis? J Eur Acad Dermatol Venereol; 2009 Aug;23(8):977-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratosis follicularis and dermatomyositis: is there a common pathogenesis?
  • [MeSH-major] Darier Disease / etiology. Dermatomyositis / etiology. Paraneoplastic Syndromes / etiology

  • Genetic Alliance. consumer health - Darier Disease.
  • Genetic Alliance. consumer health - Dermatomyositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210696.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Moloney F, Vestergaard M, Radojkovic B, Damian D: Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol; 2010 May;162(5):1138-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses.
  • [MeSH-major] Keratosis, Actinic / drug therapy. Niacinamide / therapeutic use. Vitamin B Complex / therapeutic use

  • MedlinePlus Health Information. consumer health - B Vitamins.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20199551.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 12001-76-2 / Vitamin B Complex; 25X51I8RD4 / Niacinamide
  •  go-up   go-down


29. Gold MH: Photodynamic therapy in dermatology: the next five years. Dermatol Clin; 2007 Jan;25(1):119-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its use in actinic keratoses and in non-melanoma skin cancers is well described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126750.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Garcia Carmona FJ, Pascual Huerta J, Hernandez Toledo J: Plantar epidermoid inclusion cyst as a possible cause of intractable plantar keratosis lesions. J Am Podiatr Med Assoc; 2009 Mar-Apr;99(2):148-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plantar epidermoid inclusion cyst as a possible cause of intractable plantar keratosis lesions.
  • Inclusion cysts are benign lesions that appear as a consequence of traumatic inclusion of epidermal cells into the dermis.
  • We report a case of a 36-year-old woman with an intractable plantar keratosis lesion under the third metatarsal head of 3 years' duration.
  • It was surgically excised, and pathology confirmed the diagnosis of a plantar epidermoid cyst.
  • This case should alert the clinician about the existence of keratotic lesions in the metatarsal heads commonly diagnosed and treated as intractable plantar keratosis, although they are not directly derived from metatarsal overload.
  • [MeSH-major] Epidermal Cyst / diagnosis. Epidermal Cyst / surgery. Foot Diseases / diagnosis. Foot Diseases / surgery. Keratoderma, Palmoplantar / etiology

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299353.001).
  • [ISSN] 8750-7315
  • [Journal-full-title] Journal of the American Podiatric Medical Association
  • [ISO-abbreviation] J Am Podiatr Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Hossain MK, Khan MM, Alam MA, Chowdhury AK, Delwar Hossain M, Feroze Ahmed M, Kobayashi K, Sakauchi F, Mori M: Manifestation of arsenicosis patients and factors determining the duration of arsenic symptoms in Bangladesh. Toxicol Appl Pharmacol; 2005 Oct 1;208(1):78-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanosis was common (97%) among them but about two-thirds (68.7%) of the patients were suffering from keratosis.
  • Keratosis was also significantly associated with older age (P=0.022), shallower tubewell (P<0.001), complication of conjunctivitis (P<0.001), bronchitis (P<0.001), loss of appetite (P<0.001), and wasting (P<0.001).
  • Multivariate odds ratio (OR) and 95% confidence interval (CI) indicated that keratosis (OR=2.00; 95% CI: 1.56-2.56) was significantly associated with longer duration of arsenic symptoms; loss of appetite (OR=1.40; 95% CI: 1.12-1.74) was a significant complication for longer duration.
  • [MeSH-major] Arsenic Poisoning / complications. Keratosis / etiology. Melanosis / etiology
  • [MeSH-minor] Adult. Age Distribution. Arsenic / analysis. Bangladesh / epidemiology. Chronic Disease. Conjunctivitis / diagnosis. Conjunctivitis / epidemiology. Conjunctivitis / etiology. Female. Health Surveys. Humans. Male. Middle Aged. Odds Ratio. Sex Distribution. Surveys and Questionnaires. Time Factors. Water Pollution / analysis. Water Supply / standards. Water Supply / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Arsenic.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164963.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] N712M78A8G / Arsenic
  •  go-up   go-down


32. Stollery N: Sun-related conditions. Practitioner; 2010 Jun;254(1730):35-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Carcinoma, Basal Cell / etiology. Humans. Keratosis, Actinic / etiology. Lentigo / etiology. Melanoma / etiology. PUVA Therapy / adverse effects. Photography. Skin Neoplasms / etiology. Vitiligo / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669823.001).
  • [ISSN] 0032-6518
  • [Journal-full-title] The Practitioner
  • [ISO-abbreviation] Practitioner
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, Breuer J, Majewski S, Pfister H, Wieland U: Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol; 2005 Jul;125(1):93-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers.
  • In this study viral DNA loads of six frequent HPV types were determined by quantitative, type-specific real-time-PCR (Q-PCR) in actinic keratoses (AK, n=26), NMSC (n=31), perilesional tissue (n=22), and metastases of squamous cell carcinomas (SCC) (n=8) which were previously shown to be positive for HPV5, 8, 15, 20, 24, or 36.
  • HPV-DNA loads in AK, (partially microdissected) NMSC, and perilesional skin ranged between one HPV-DNA copy per 0.02 and 14,200 cell equivalents (median: 1 HPV-DNA copy per 344 cell equivalents; n=48).
  • But, viral loads found in AK were significantly higher than in SCC (p=0.035).
  • [MeSH-major] Carcinoma, Squamous Cell / virology. DNA Probes, HPV. DNA, Viral / analysis. Keratosis / virology. Papillomaviridae / isolation & purification. Skin Neoplasms / virology. Viral Load

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Invest Dermatol. 2005 Jul;125(1):xii-xiii [15982294.001]
  • (PMID = 15982308.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral
  •  go-up   go-down


34. Falagas ME, Angelousi AG, Peppas G: Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. J Am Acad Dermatol; 2006 Sep;55(3):537-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Keratosis / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908371.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Letter; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


35. Maharjan M, Shrestha RR, Ahmad SA, Watanabe C, Ohtsuka R: Prevalence of arsenicosis in terai, Nepal. J Health Popul Nutr; 2006 Jun;24(2):246-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin manifestations, such as melanosis and keratosis, were the common symptoms of arsenicosis.
  • Most patients were identified in the early or mild stage of the disease.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Epidemiologic Studies. Female. Geography. Humans. Keratosis / chemically induced. Male. Melanosis / chemically induced. Middle Aged. Nepal / epidemiology. Population Surveillance. Prevalence. Risk Factors. Severity of Illness Index. Sex Distribution. Tropical Climate. Water Supply / analysis. Water Supply / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Arsenic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195566.001).
  • [ISSN] 1606-0997
  • [Journal-full-title] Journal of health, population, and nutrition
  • [ISO-abbreviation] J Health Popul Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


36. Scott IS, Odell E, Chatrath P, Morris LS, Davies RJ, Vowler SL, Laskey RA, Coleman N: A minimally invasive immunocytochemical approach to early detection of oral squamous cell carcinoma and dysplasia. Br J Cancer; 2006 Apr 24;94(8):1170-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical examination of 66 oral tissue samples showed a greater frequency of Mcm-2 expression in surface layers of moderate/severe dysplasia and SCC compared to benign keratosis/mild dysplasia.
  • Conventional smears included 23 from normal mucosa, benign proliferative disease and mild dysplasia, all of which were MCM negative.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / diagnosis. Cell Cycle Proteins / analysis. Mouth Neoplasms / diagnosis. Nuclear Proteins / analysis. Precancerous Conditions / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Dis. 2000 Mar;6(2):65-74 [10702782.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):135-41 [15660109.001]
  • [Cites] Nat Cell Biol. 2002 Mar;4(3):198-207 [11836525.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1917-9 [12057556.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1048-54 [12966424.001]
  • [Cites] J Pathol. 2003 Oct;201(2):187-97 [14517835.001]
  • [Cites] Br J Cancer. 1971 Mar;25(1):21-4 [5581297.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):184-94 [8417385.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):861-72 [8631307.001]
  • [Cites] Bioessays. 1996 Mar;18(3):183-90 [8867732.001]
  • [Cites] Exp Cell Res. 1998 May 25;241(1):260-4 [9633535.001]
  • [Cites] Biochim Biophys Acta. 1998 Jun 16;1398(2):113-36 [9689912.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):187-93 [11437923.001]
  • (PMID = 16622441.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359878
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2361243
  •  go-up   go-down


37. Ferrara G, Zalaudek I, Cabo H, Soyer HP, Argenziano G: Collision of basal cell carcinoma with seborrhoeic keratosis: a dermoscopic aid to histopathology? Clin Exp Dermatol; 2005 Sep;30(5):586-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision of basal cell carcinoma with seborrhoeic keratosis: a dermoscopic aid to histopathology?
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratosis, Seborrheic / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Exp Dermatol. 2004 Mar;29(2):199-200 [14987284.001]
  • (PMID = 16045704.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


38. Haake DL, Minni JP, Nowak M, Abenoza P, Nousari CH: Reticulated acanthoma with sebaceous differentiation. Lack of association with Muir-Torre syndrome. Am J Dermatopathol; 2009 Jun;31(4):391-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We hereby report a case of a reticulated acanthoma with sebaceous differentiation (RASD), a rare and often mislabeled benign lesion that is characterized by epidermal acanthosis and clusters of sebocytes in a reticulated seborrheic keratosis-like pattern.

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • Genetic Alliance. consumer health - Acanthoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461247.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Clementoni MT, B-Roscher M, Munavalli GS: Photodynamic photorejuvenation of the face with a combination of microneedling, red light, and broadband pulsed light. Lasers Surg Med; 2010 Feb;42(2):150-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: High efficacy and safety, coupled with in-office, short contact protocols have made photodynamic therapy (PDT) with aminolevulenic acid (ALA) for the treatment of actinic keratoses a mainstay option over the last decade.
  • The study objective was to maximize epidermal penetration and subsequent activation of ALA for the treatment of photodamaged facial skin, utilizing a microneedle roller prior to incubation and combined irradiation with red light and broadband pulsed light in a single treatment.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20166166.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


40. Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J: The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol; 2007 May;156 Suppl 3:25-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diclofenac is the anti-neoplastic compound in diclofenac 3% gel (Solaraze) used for topical treatment of actinic keratosis (AK).
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Angiogenesis Inducing Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Cell Proliferation / drug effects. Diclofenac / therapeutic use. Humans. Keratosis / drug therapy. Prostaglandins / biosynthesis

  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488403.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Angiogenesis Inducing Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Prostaglandins; 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid
  • [Number-of-references] 84
  •  go-up   go-down


46. Cushing SL, MacDonald L, Propst EJ, Sharma A, Stockley T, Blaser SL, James AL, Papsin BC: Successful cochlear implantation in a child with Keratosis, Icthiosis and Deafness (KID) Syndrome and Dandy-Walker malformation. Int J Pediatr Otorhinolaryngol; 2008 May;72(5):693-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful cochlear implantation in a child with Keratosis, Icthiosis and Deafness (KID) Syndrome and Dandy-Walker malformation.
  • Keratosis, Icthiosis, and Deafness (KID) Syndrome is a rare congenital disorder associated with dominant connexin 26 mutations, affecting epidermis, corneal epithelium, and inner ear.
  • [MeSH-major] Cochlear Implantation. Dandy-Walker Syndrome / complications. Hearing Loss, Sensorineural / therapy. Ichthyosis / complications. Keratosis / complications


47. Bchetnia M, Benmously R, Ben Brick AS, Charfeddine C, Ben Ameur Y, Fajraoui M, Debbiche A, Ben Ayed M, Mokni M, Fenniche S, Mokhtar I, Abdelhak S: New mutations of Darier disease in Tunisian patients. Arch Dermatol Res; 2009 Sep;301(8):615-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New mutations of Darier disease in Tunisian patients.
  • Darier's disease (DD, MIM 124200) also known as Darier-White disease and keratosis follicularis, is a rare autosomal dominant skin disorder characterized by warty papules and plaques in the seborrheic area (central trunk, flexures, scalp, and forehead).
  • Pathogenic mutations in the ATP2A2 gene encoding the sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase (SERCA) 2 gene underlie the disease.
  • Our findings provide further evidence for the genetic heterogeneity of DD in Tunisia and that most mutations involved in this disease are family specific.
  • [MeSH-major] Darier Disease / metabolism. Mutation. Sarcoplasmic Reticulum Calcium-Transporting ATPases / genetics

  • Genetic Alliance. consumer health - Darier Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19488774.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.6.3.8 / ATP2A2 protein, human; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases
  •  go-up   go-down


48. Mitsuhashi Y, Kawaguchi M, Hozumi Y, Kondo S: Topical vitamin D3 is effective in treating senile warts possibly by inducing apoptosis. J Dermatol; 2005 Jun;32(6):420-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical vitamin D3 is effective in treating senile warts possibly by inducing apoptosis.
  • Senile wart or seborrheic keratosis is a benign tumor which occurs mainly in the elderly.
  • We treated senile warts with topical vitamin D3 ointments (tacalcitol, calcipotriol or maxacalcitol).
  • An organ culture experiment using senile wart as a material with several concentrations of tacalcitol revealed that tacalcitol induced apoptosis in the tissue.
  • Vitamin D3 may affect senile warts by inducing apoptosis.
  • Clearance of senile warts, especially on exposed areas without pain, may improve the quality of life (QOL) of the elderly.
  • [MeSH-major] Cholecalciferol / therapeutic use. Keratosis, Seborrheic / drug therapy. Keratosis, Seborrheic / pathology

  • Hazardous Substances Data Bank. CHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043912.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1C6V77QF41 / Cholecalciferol
  •  go-up   go-down


49. Bongiorno MR, Aricò M: Progressive symmetric erythro-keratosis associated with oligodontia, severe caries, disturbed hair growth and ectopic nail: a new syndrome? Dermatology; 2008;217(4):347-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive symmetric erythro-keratosis associated with oligodontia, severe caries, disturbed hair growth and ectopic nail: a new syndrome?
  • Histological examination showed marked hyperkeratosis with parakeratosis, and a thickened granular cell layer, mild acanthosis and slight lymphocytic infiltration surrounding the papillary blood vessels, compatible with a diagnosis of progressive symmetrical erythro-keratosis.
  • Progressive symmetric erythro-keratosis has so far been described as a non-syndromic skin disorder, which is why our patient's multisystem birth defect may represent a new entity.
  • [MeSH-major] Abnormalities, Multiple / pathology. Anodontia / pathology. Dental Caries. Hair / pathology. Hyperkeratosis, Epidermolytic / pathology. Nails / pathology
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Syndrome

  • MedlinePlus Health Information. consumer health - Tooth Decay.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18799882.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


50. Rivers JK, Rosoph L, Provost N, Bissonnette R: Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head. J Cutan Med Surg; 2008 May-Jun;12(3):97-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head.
  • BACKGROUND: Local skin reactions are common during imiquimod treatment of actinic keratosis (AK).
  • OBJECTIVE: To assess the tolerability of imiquimod and clearance rate of AK lesions after imiquimod application.
  • METHODS: Imiquimod 5% cream was administered three times per week for 4 weeks followed by 4 weeks of rest (cycle 1) to AK lesions on the head.
  • If AK lesions remained visible at the end of cycle 1, a second treatment cycle was instituted.
  • RESULTS: Fifty percent (30 of 60) of patients experienced complete clearance of AK lesions, and 75% (30 of 40) of patients experienced partial clearance of AK lesions after imiquimod treatment at the end of cycle 2.
  • Moreover, 77% of patients who achieved complete clearance had no visible AK lesions 12 weeks post-treatment.
  • CONCLUSION: Imiquimod cycle therapy may be a safe and effective treatment option for AK lesions.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Head. Keratosis / drug therapy

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544290.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Ointments; P1QW714R7M / imiquimod
  •  go-up   go-down


51. Badura-Stronka M, Jamsheer A, Materna-Kiryluk A, Sowińska A, Kiryluk K, Budny B, Latos-Bieleńska A: A novel nonsense mutation in CUL4B gene in three brothers with X-linked mental retardation syndrome. Clin Genet; 2010 Feb;77(2):141-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the symptoms, we made a clinical diagnosis of Cabezas syndrome, which was subsequently confirmed by identification of a novel nonsense mutation (c.2107A-->T, p.703K-->X) in exon 18 of the CUL4B gene.
  • In addition to previously described symptoms, syndactyly of the second and third toes and skin manifestations (hyperhydrosis and keratosis pilaris) were present in our cases.


52. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A: Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum; 2005 Aug;52(8):2513-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe 5 patients in whom psoriasiform skin lesions developed 6-9 months after the initiation of anti-TNF therapy for longstanding, seropositive rheumatoid arthritis (etanercept or adalimumab), typical ankylosing spondylitis (infliximab), and Adamantiades-Behçet's disease (infliximab).
  • In all 5 patients, the underlying disease had responded well to anti-TNF therapy.
  • In 3 patients there was nail involvement with onycholysis, yellow discoloration, and subungual keratosis.

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Etanercept .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052599.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  •  go-up   go-down


53. Fernández-Guarino M, Harto A, Pérez-Garcia B, Martin-González M, Urrutia S, Jaén P: Photodynamic therapy in disseminated superficial actinic porokeratosis. J Eur Acad Dermatol Venereol; 2009 Feb;23(2):176-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy in disseminated superficial actinic porokeratosis.
  • [MeSH-major] Keratosis, Actinic / drug therapy. Photochemotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18429984.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


54. Fernández A, Marcén R, Pascual J, Galeano C, Ocaña J, Arellano EM, Alfaro C, Villafruela JJ, Burgos FJ, Ortuño J: Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc; 2006 Oct;38(8):2453-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
  • One patient with posttransplant lymphoproliferative disease also received chemotherapy with a good evolution at 6 months.
  • The other six patients with recurrent skin cancers had good cancer evolution, with no new skin tumors and regression of skin lesions in three, including not biopsied actinic keratosis.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097965.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


55. Saeed S, Sagatys E, Morgan MB: Acral keratosis with eosinophilic dermal deposits: a distinctive clinicopatholgic entity or colloid milium redux? J Cutan Pathol; 2006 Oct;33(10):679-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acral keratosis with eosinophilic dermal deposits: a distinctive clinicopatholgic entity or colloid milium redux?
  • AIMS: The differential diagnosis of acral keratoses is broad.
  • Encompassing a variety of infectious, heritable and degenerative disorders, emphasis upon the clinical setting and histologic subtlety are often required to arrive at the correct diagnosis.
  • Potential sources of the material and a discussion of the differential diagnosis follow.
  • [MeSH-major] Eosinophilia / pathology. Keratosis / pathology. Skin Diseases / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fingers / pathology. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026520.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


56. Hussein MR, Ahmed RA: Analysis of the mononuclear inflammatory cell infiltrate in the non-tumorigenic, pre-tumorigenic and tumorigenic keratinocytic hyperproliferative lesions of the skin. Cancer Biol Ther; 2005 Aug;4(8):819-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the mononuclear inflammatory cell infiltrate in the non-tumorigenic, pre-tumorigenic and tumorigenic keratinocytic hyperproliferative lesions of the skin.
  • BACKGROUND: The keratinocytic hyperproliferative lesions include non-tumorigenic, pre-tumorigenic (actinic keratoses, AK), and tumorigenic (squamous cell carcinomas, SCC) conditions.
  • We hypothesized that the development of non-tumorigenic, pre-tumorigenic, and tumorigenic keratinocytic hyperproliferative lesions is associated with alterations in the mononuclear inflammatory cell infiltrate in response to altered antigenicity of the lesional cells.
  • METHODS: Fifty lesions (non-tumorigenic lesions, 29; AK, 9 and SCC, 12) were examined using immunoperoxidase staining methods and antibodies targeting histiocytes (CD68), T cells (CD3), B cells (CD20), and T cells with cytotoxic potential (TIA-1).
  • RESULTS: As compared to the normal skin, the development of the keratinocytic hyperproliferative lesions (normal skin; non-tumorigenic; AK and SCC) was associated with a statistically significant increase (p = <0.05) in:.
  • [MeSH-minor] Antigens, CD / analysis. Cells, Cultured. Humans. Keratosis / immunology. Keratosis / pathology. Poly(A)-Binding Proteins / analysis. Skin / cytology. Skin / immunology. Skin / pathology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16210913.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Poly(A)-Binding Proteins; 0 / TIA1 protein, human
  •  go-up   go-down


57. Hafner C, Di Martino E, Pitt E, Stempfl T, Tomlinson D, Hartmann A, Landthaler M, Knowles M, Vogt T: FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. Exp Cell Res; 2010 Jul 15;316(12):2008-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FGFR3 mutations have recently been identified in several benign epidermal skin lesions such as seborrheic keratosis, epidermal nevus and solar lentigo.

  • Genetics Home Reference. consumer health - epidermal nevus.
  • Genetics Home Reference. consumer health - FGFR3 gene.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420824.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


58. Dika E, Balestri R, Vaccari S, Fanti PA, Patrizi A: Peculiar recurrence of malignant melanoma: metastases on cutaneous scars and peritoneal carcinomatosis. Eur J Dermatol; 2010 Sep-Oct;20(5):653-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Aged. Dysplastic Nevus Syndrome / pathology. Dysplastic Nevus Syndrome / surgery. Fatal Outcome. Female. Humans. Keratosis, Actinic / pathology. Keratosis, Actinic / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Scars.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20605775.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


59. Bernard P, Dupuy A, Brun P, Sasko A, Duru G, Nicoloyannis N, Decuypere L, Grob JJ: [Therapeutic modalities and economic assessment in the treatment of superficial basal cell carcinomas and multiple actinic keratoses by French dermatologists]. Ann Dermatol Venereol; 2007 Jun-Jul;134(6-7):527-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic modalities and economic assessment in the treatment of superficial basal cell carcinomas and multiple actinic keratoses by French dermatologists].
  • INTRODUCTION: To date, no prospective studies have been conducted in France describing the management of actinic keratoses (AK) and superficial basal cell carcinomas (sBCC).
  • The aim of the present study was to describe the therapeutic modalities for AK and sBCC adopted by French dermatologists and to determine the direct annual medical costs.
  • The therapeutic modalities, the physicians involved and the laboratory examinations during the 3 months following diagnosis were recorded prospectively.
  • Histological confirmation of diagnosis of BCC was obtained in 85% of cases.
  • In addition, 226 patients with AK (mean age: 76 years; sex-ratio M/F: 2.1) were included in the study.
  • DISCUSSION: This is the first study conducted in France to evaluate both the medical approach and treatment costs of sBCC and AK.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657178.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


60. Ferringer T, Rogers HC, Metcalf JS: Merkel cell carcinoma in situ. J Cutan Pathol; 2005 Feb;32(2):162-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidermal involvement is unusual and MCC limited to the epidermis is very rare.
  • An intraepidermal proliferation of small blue cells distributed in nests and single units at all levels of the epidermis was found within a solar keratosis and adjacent to an area of squamous cell carcinoma in situ.
  • [MeSH-minor] Aged. Diagnosis, Differential. Epidermis / metabolism. Epidermis / pathology. Epidermis / surgery. Humans. Male

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606676.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


61. Drukała J, Bobis S, Zabińska-Płazak E, Wojas-Pelc A: [Molecular basis of pigmentation disorders in skin diseases]. Przegl Lek; 2009;66(3):145-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this work we focused on molecular basis of pigmentation disorders in dermatological diseases that present clinically with hyperpigmentation (lentigo senilis, Riehl melanosis, seborrhoic keratosis, fibroma, café-au-lait patches melasma, atopic dermatitis) or hypopigmentation (vitiligo, albinism).
  • [MeSH-minor] Diagnosis, Differential. Humans. Hyperpigmentation / diagnosis. Hyperpigmentation / metabolism. Hypopigmentation / diagnosis. Hypopigmentation / metabolism. Melatonin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • Hazardous Substances Data Bank. MELATONIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689040.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] JL5DK93RCL / Melatonin
  • [Number-of-references] 24
  •  go-up   go-down


62. Nagore E, Botella-Estrada R, Requena C, Serra-Guillén C, Martorell A, Hueso L, Llombart B, Sanmartín O, Guillén C: [Clinical and epidemiologic profile of melanoma patients according to sun exposure of the tumor site]. Actas Dermosifiliogr; 2009 Apr;100(3):205-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Perfil clínico y epidemiológico de los pacientes con melanoma cutáneo según el grado de exposición solar de la localización del melanoma.
  • The second largest group was formed by patients with tumors on areas chronically exposed to sun and that had all the clinical lesions (solar lentigines and actinic keratoses) and epidemiological characteristics typical of these areas.
  • Finally, patients with melanomas on areas not exposed to sun were older, as occurred in the group with chronic exposure, and the diagnosis was made at more advanced stages of the disease.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / epidemiology. Skin Neoplasms / diagnosis. Skin Neoplasms / epidemiology. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19457306.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


63. Han YW, Kim YJ, Kim HO, Park YM: Clinical Study of Porokeratosis Associated with Immunosuppressive Therapy in Renal Transplant Recipients. Ann Dermatol; 2008 Dec;20(4):167-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients had disseminated superficial actinic PK (DSAP), PK Mibelli, or both types.
  • Associated diseases included verruca (4), recurrent herpes simplex (1), actinic keratosis (1), and cutaneous B cell lymphoma (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27303185.001).
  • [ISSN] 1013-9087
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4903972
  • [Keywords] NOTNLM ; Immunosuppression / Porokeratosis / Renal transplantation
  •  go-up   go-down


64. von Felbert V, Neis M, Megahed M, Spöler F: [Imaging of actinic porokeratosis by optical coherence tomography (OCT)]. Hautarzt; 2008 Nov;59(11):877-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Imaging of actinic porokeratosis by optical coherence tomography (OCT)].
  • Disseminated superficial actinic porokeratosis (DSAP) is a rare, genetically heterogeneous skin disorder.
  • During the last 4 years prior to diagnosis, she had developed numerous (pre)malignant lesions of the skin of the lower legs including actinic keratoses, squamous cell carcinomas and Bowen's disease.
  • DSAP lesions and actinic keratoses were resistant to topical treatment with imiquimod and retinoids, but improved with photodynamic therapy (PDT).
  • [MeSH-major] Dermoscopy / methods. Image Enhancement / methods. Keratosis, Actinic / drug therapy. Keratosis, Actinic / pathology. Leg Dermatoses / drug therapy. Tomography, Optical Coherence / methods
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Photochemotherapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2005 Jun;152(6):1389-91 [15949029.001]
  • [Cites] Skin Res Technol. 2001 Feb;7(1):1-9 [11301634.001]
  • [Cites] Hum Genet. 2008 Jun;123(5):507-13 [18443824.001]
  • [Cites] Dermatol Surg. 1996 Apr;22(4):339-42 [8624658.001]
  • [Cites] Br J Dermatol. 2002 Oct;147(4):650-4 [12366408.001]
  • (PMID = 18931984.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Takahashi H, Nakajima S, Sakata I, Ishida-Yamamoto A, Iizuka H: Photodynamic therapy using a novel photosensitizer, ATX-S10(Na): comparative effect with 5-aminolevulinic acid on squamous cell carcinoma cell line, SCC15, ultraviolet B-induced skin tumor, and phorbol ester-induced hyperproliferative skin. Arch Dermatol Res; 2005 Apr;296(10):496-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) is available for the treatment of actinic keratosis (AK).
  • Recently, we developed a new PDT photosensitizer, ATX-S10(Na), and have shown that ATX-S10(Na) PDT is effective for the treatment of various human skin diseases, such as squamous cell carcinoma, Bowen's disease, basal cell carcinoma, and psoriasis.
  • TPA treatment induced epidermal acanthosis, which was more markedly suppressed by ATX-S10(Na) PDT than by ALA PDT.
  • ATX-S10(Na) PDT more effectively eliminated UVB-induced AK and squamous cell carcinoma (SCC) than ALA PDT.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15759135.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ATX S10Na(II); 0 / Porphyrins; 88755TAZ87 / Aminolevulinic Acid; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


66. Martínez A, Spencer ML, Brethauer U, Grez P, Marchesani FJ, Rojas IG: Reduction of syndecan-1 expression during lip carcinogenesis. J Oral Pathol Med; 2009 Aug;38(7):580-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Actinic cheilitis (AC) is an oral pre-cancerous lesion that sometimes develops into lip squamous cell carcinoma (SCC).
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cheilitis / metabolism. Keratosis, Actinic / metabolism. Lip Neoplasms / metabolism. Syndecan-1 / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473447.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Syndecan-1
  •  go-up   go-down


67. Ulrich M, Stockfleth E: Field treatment of actinic keratoses - focus on COX-2-inhibitors. Actas Dermosifiliogr; 2009 Dec;100 Suppl 2:55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Field treatment of actinic keratoses - focus on COX-2-inhibitors.
  • Actinic keratoses (AK) represent the most common carcinoma in situ of the skin and show continuously increasing incidences worldwide.
  • Clinically, AK occur as multiple lesions in sun-exposed areas, which has been referred to as field cancerization.
  • Novel treatment modalities for actinic field cancerization include 3 % diclofenac in 2.5 % hyaluronic acid (HA).
  • Herein, we give an overview about actinic keratosis focusing on treatment with the COX-2 inhibitor diclofenac 3 % gel and summarize current concepts of its antineoplastic mode of action.
  • [MeSH-major] Cyclooxygenase 2 Inhibitors / therapeutic use. Keratosis, Actinic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096163.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors
  •  go-up   go-down


68. Muston D, Downs A, Rives V: An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat; 2009;20(5):266-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An economic evaluation of topical treatments for actinic keratosis.
  • Actinic keratoses (AK) commonly occur as lesions, in sun-exposed areas.
  • We assessed the cost-effectiveness in 2007 of topical treatments (5-fluorouracil, imiquimod) and photodynamic therapy with methyl aminolevulinate (MAL-PDT) for AK under the perspective of the UK National Health Service (NHS) in England and Wales over two lines of treatment.
  • Based on this model, the costs and effectiveness of MAL-PDT in the UK NHS compare well with other treatments for AK.
  • [MeSH-major] Antineoplastic Agents / economics. Keratosis, Actinic / economics. Keratosis, Actinic / therapy. Photochemotherapy / economics. Photosensitizing Agents / economics

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Dermatolog Treat. 2011 Oct;22(5):298-301 [20666679.001]
  • (PMID = 19421918.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


69. Zaravinos A, Kanellou P, Baritaki S, Bonavida B, Spandidos DA: BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. Cell Cycle; 2009 May 1;8(9):1402-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Actinic keratosis (AK) is a well-established pre-cancerous skin lesion that has the potential to progress to squamous cell carcinoma (SCC).
  • OBJECTIVES: This study aimed to measure the mRNA levels of the genes BRAF and RKIP in AK, as well as their possible implication in the progress of AK to SCC.
  • RKIP expression levels were significantly higher than the corresponding levels of BRAF (p < 0.001), whereas the two genes showed a negative correlation not only in AK and SCC, but in the adjacent phenotypically normal skin tissue, as well.
  • No mutation was detected, either in AK or SCC, within exons 11 and 15 of the BRAF gene.
  • CONCLUSION: Both BRAF and RKIP expression levels exhibit a decrease from normal skin tissue and AK, going to SCC.
  • Our results further indicate that BRAF does not appear to be frequently mutated either in pre-cancerous skin lesions (AK) or in non-melanoma skin tumors (SCC).


70. Sachs DL, Kang S, Hammerberg C, Helfrich Y, Karimipour D, Orringer J, Johnson T, Hamilton TA, Fisher G, Voorhees JJ: Topical fluorouracil for actinic keratoses and photoaging: a clinical and molecular analysis. Arch Dermatol; 2009 Jun;145(6):659-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical fluorouracil for actinic keratoses and photoaging: a clinical and molecular analysis.
  • OBJECTIVE: To examine clinical and molecular changes after topical fluorouracil treatment of photodamaged human facial skin for actinic keratoses.
  • PATIENTS: Twenty-one healthy volunteers, 56 to 85 years old, with actinic keratoses and photodamage.
  • MAIN OUTCOME MEASURES: Gene and protein expression of molecular effectors of epidermal injury, inflammation, and extracellular matrix remodeling 24 hours after fluorouracil treatment; clinical improvement measured by evaluators, photography, and patient questionnaires.
  • RESULTS: One day after the final fluorouracil treatment, gene expression of the effectors of epidermal injury (keratin 16), inflammation (interleukin 1beta), and extracellular matrix degradation (matrix metalloproteinases 1 and 3) was significantly increased.
  • Actinic keratoses and photoaging were statistically significantly improved.
  • CONCLUSIONS: Topical fluorouracil causes epidermal injury, which stimulates wound healing and dermal remodeling resulting in improved appearance.
  • [MeSH-major] Fluorouracil / therapeutic use. Keratosis, Actinic / drug therapy. Skin Aging / drug effects


71. El-Zawahry MB, Abdel El-Hameed El-Cheweikh HM, Abd-El-Rahman Ramadan S, Ahmed Bassiouny D, Mohamed Fawzy M: Ultrasound biomicroscopy in the diagnosis of skin diseases. Eur J Dermatol; 2007 Nov-Dec;17(6):469-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound biomicroscopy in the diagnosis of skin diseases.
  • We aimed to evaluate the accuracy of ultrasound biomicroscopy (UBM) in the diagnosis of eight skin disorders namely, morphea, keloid, lichen planus, chronic eczema, psoriasis, port wine stain, seborrheic keratosis, and photo-aged skin, through correlation of its findings with clinical and pathological assessment.
  • In morphea, the dermal echogenicity was increased and the thickness of morphea plaques correlated significantly with disease severity.
  • Seborrheic keratosis appeared as a sound shadow.
  • We conclude that UBM is a non-invasive diagnostic tool in dermatology which can be used to give valuable information about disease progress and the effectiveness of therapy.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951126.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


72. Abbas O, Mahalingam M: Tumor of the follicular infundibulum: an epidermal reaction pattern? Am J Dermatopathol; 2009 Oct;31(7):626-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor of the follicular infundibulum: an epidermal reaction pattern?
  • To clarify the defining clinical and microscopic features of TFI with special relevance to the histologic variants, we retrospectively reviewed cases with a histologic diagnosis of TFI between 1999 and 2008.
  • Of interest, approximately one fourth (25%) were associated with other cutaneous lesions, which included basal cell carcinoma, actinic keratosis, desmoplastic malignant melanoma, junctional melanocytic nevus, tricholemmoma, and epidermal inclusion cyst.
  • In addition to expanding the constellation of the clinical and histopathologic findings, the increased association with other cutaneous lesions in the current study suggests that TFI may represent an epidermal reaction pattern.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633534.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Grüning N, Müller-Goymann CC: Physicochemical characterisation of a novel thermogelling formulation for percutaneous penetration of 5-aminolevulinic acid. J Pharm Sci; 2008 Jun;97(6):2311-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present contribution was dedicated to the development and characterisation of a semisolid formulation of 5-aminolevulinic acid (5-ALA), appropriate for the diagnosis and treatment of actinic keratosis in photodynamic therapy.

  • Hazardous Substances Data Bank. ISOSORBIDE .
  • Hazardous Substances Data Bank. ISOPROPANOL .
  • Hazardous Substances Data Bank. Water .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17828744.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Drug Carriers; 0 / Gels; 0 / Ointments; 0 / Triglycerides; 059QF0KO0R / Water; 106392-12-5 / Poloxamer; 88755TAZ87 / Aminolevulinic Acid; ND2M416302 / 2-Propanol; WXR179L51S / Isosorbide
  •  go-up   go-down


74. Albares Tendero MP, Belinchón Romero I, Ramos Rincón JM, Sánchez Payá J, Costa AL, Pérez Crespo M, Silvestre Salvador JF: Dermatoses in Latin American immigrants seen in a tertiary hospital. Eur J Dermatol; 2009 Mar-Apr;19(2):157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The comparative study of dermatoses adjusted for age and sex, found a greater frequency of eczema, alopecia, melasma, herpes simplex, pilar keratosis, xerosis, and scabies (p < 0.01) in the Latin American population.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106052.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


75. Silva RS, Fonseca JC, Obadia D: Case for diagnosis. Erythromelanosis follicularis faciei et colli. An Bras Dermatol; 2010 Nov-Dec;85(6):923-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case for diagnosis. Erythromelanosis follicularis faciei et colli.
  • Erythromelanosis follicularis faciei et colli is a rare disease of unknown etiology characterized by symmetric erythematous brownish hyperpigmentation on the frontal, malar and temporal areas associated with involvement of the pilary follicle.
  • It is common to present pilar keratosis on the shoulders and neck.
  • [MeSH-major] Darier Disease / pathology. Facial Dermatoses / pathology. Hyperpigmentation / pathology. Melanosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308325.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


76. Nestor MS, Gold MH, Kauvar AN, Taub AF, Geronemus RG, Ritvo EC, Goldman MP, Gilbert DJ, Richey DF, Alster TS, Anderson RR, Bank DE, Carruthers A, Carruthers J, Goldberg DJ, Hanke CW, Lowe NJ, Pariser DM, Rigel DS, Robins P, Spencer JM, Zelickson BD: The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol; 2006 Feb;5(2):140-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The experts established consensus statements for pretreatment, posttreatment, ALA contact time, light sources, and numbers of sessions associated with ALA PDT for actinic keratosis and superficial basal cell carcinoma, photorejuvenation and cosmetic enhancement, acne, sebaceous skin, rosacea, and rhinophyma.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485882.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 125
  •  go-up   go-down


77. Stockfleth E, Sterry W, Carey-Yard M, Bichel J: Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol; 2007 Dec;157 Suppl 2:41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head.
  • OBJECTIVE: In the USA, Imiquimod 5% cream is approved for use 2-3 times per week over 16 weeks for the treatment of actinic keratoses (AKs).
  • PATIENTS: Patients were eligible if they had clinically typical, visible AK lesions located anywhere on the head, excluding the upper and lower eyelids, nostrils, lip vermilion, and inside the ears.
  • Patients with AK lesions remaining in the treatment area underwent a second 4-week treatment course.
  • MAIN OUTCOME MEASURES: Primary variable was the complete clearance rate, defined as the proportion of patients with no clinically visible AK lesions in the treatment area at the course 1 or course 2 post-treatment visit.
  • Overall, the complete clearance rate was 68.9% (571/829) and the partial clearance rate (percentage of patients with >/= 75% reduction in the number of baseline AK lesions) was 80.2%.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Facial Neoplasms / drug therapy. Keratosis / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067631.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


78. Ulrich M, Maltusch A, Röwert-Huber J, González S, Sterry W, Stockfleth E, Astner S: Actinic keratoses: non-invasive diagnosis for field cancerisation. Br J Dermatol; 2007 May;156 Suppl 3:13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses: non-invasive diagnosis for field cancerisation.
  • BACKGROUND: Actinic keratoses (AKs) are among the most common cutaneous malignancies and have previously been classified as in situ squamous cell carcinoma (SCC) with reported progression rates of up to 20% over 10 years.
  • In vivo reflectance confocal microscopy (RCM) has been used for evaluation of the morphological features of non-melanoma skin cancer (NMSC) and RCM evaluation parameters for the diagnosis of AKs have been reported.
  • PATIENTS/METHODS: Forty four Caucasians (SPT I-III) with a minimum of one actinic keratosis (AK) lesion were included in this study.
  • Following blinded evaluation by two independent investigators, 97.7% of all skin samples were identified as AK using RCM.
  • 2.3% were incorrectly identified as normal skin by RCM, while routine histology showed features consistent with AK.
  • CONCLUSIONS: Reflectance confocal microscopy may be a feasible alternative in the diagnosis of AK and may aid in the differentiation against normal skin, as well as in the detection of subclinical disease.
  • [MeSH-major] Keratosis / pathology. Precancerous Conditions / pathology. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Disease Progression. Humans. Microscopy, Confocal / methods. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488401.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


79. Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, Zangen DH, Raas-Rothschild A, Ben-Neriah Z, Shweiki S, Elpeleg O, Zlotogorski A: The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol; 2008 Jul;59(1):79-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of cutaneous hyperpigmented, hypertrichotic, and indurated patches associated with hearing loss, short stature, cardiac anomalies, hepatosplenomegaly, scrotal masses, and hypogonadism has not, to our knowledge, been previously recognized as a disease entity.
  • Cutaneous histopathologic examination showed hyperpigmentation of the basal layer with seborrheic-keratosis-like acanthosis, histiocytic infiltration, and a perivascular mononuclear infiltrate with plasma cells and mast cells throughout the dermis and subcutaneous fat.
  • CONCLUSIONS: We suggest that our patients represent a novel multisystemic autosomal recessive inherited disorder.
  • [MeSH-major] Hearing Loss, Sensorineural / diagnosis. Hyperpigmentation / diagnosis. Hypertrichosis / diagnosis. Skin Diseases, Genetic / diagnosis
  • [MeSH-minor] Adolescent. Adult. Biopsy. Consanguinity. Female. Fibrosis. Genital Diseases, Male / diagnosis. Heart Defects, Congenital / diagnosis. Hepatomegaly / diagnosis. Humans. Lymph Nodes / pathology. Male. Phenotype. Skin / pathology. Splenomegaly / diagnosis. Syndrome

  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2009 Oct;61(4):725-7 [19664849.001]
  • [CommentIn] J Am Acad Dermatol. 2009 Aug;61(2):365 [19615552.001]
  • (PMID = 18410979.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Legoupil D, Lemasson G, Davaine AC, Misery L: [Bowen's disease and squamous cell carcinoma in Haber's syndrome: two cases]. Ann Dermatol Venereol; 2007 Jan;134(1):59-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bowen's disease and squamous cell carcinoma in Haber's syndrome: two cases].
  • Clinically, it is associated with rosaceiform dermatosis of the face that begins in childhood, and profuse keratotic lesions resembling seborrheic keratoses, seen predominantly on the trunk, the tops of the limbs and the scalp.
  • We report two cases of Bowen's disease and cutaneous epidermoid carcinoma in Haber's syndrome patients.
  • Histological examination of a biopsy sample confirmed the clinical diagnosis of Bowen's disease.
  • We propose the hypothesis of transformation of the keratoses seen in seborrheic keratosis.
  • The use of imiquimod to treat lesions in patients with Bowen's disease resulted in complete cure.
  • [MeSH-major] Bowen's Disease / complications. Carcinoma, Squamous Cell / complications. Keratosis / complications. Neoplasms, Multiple Primary / complications. Rosacea / complications. Skin Neoplasms / complications


81. Fuchs A, Marmur E: The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg; 2007 Sep;33(9):1099-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma.
  • BACKGROUND: Actinic keratoses (AKs) are intraepidermal skin tumors that have the potential to progress to squamous cell carcinomas (SCCs).
  • METHODS: To determine the time scale of AK progression, we conducted a retrospective electronic medical record study of all patients diagnosed histopathologically with an SCC between July 1, 2003, and June 30, 2005.
  • RESULTS: Of a total patient population of 6,691, 91 had a histopathologically confirmed diagnosis of an AK at the same site as the subsequent SCC.
  • The length of time for an AK to progress to an SCC was determined to be 24.6 months (95% confidence interval, 21.04-28.16 months).
  • CONCLUSIONS: Although a more controlled in vivo study is indicated, these data provide a good estimate of the time course from an AK to an SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Disease Progression. Humans. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760601.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Tyrrell JS, Campbell SM, Curnow A: The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome. Lasers Surg Med; 2010 Sep;42(7):613-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study assessed the capability of a non-invasive fluorescence imaging system (Dyaderm, Biocam, Germany), to monitor changes in PpIX during real time methyl-aminolevulinate (MAL) PDT in dermatological lesions, and thus to act as a predictive tool in terms of observed clinical outcome post-treatment.
  • MATERIALS AND METHODS: Patients attending Royal Cornwall Hospital (Truro, UK) for MAL-PDT to licensed lesions (actinic keratosis, Bowen's disease, and basal cell carcinoma) were monitored using the pre-validated non-invasive fluorescence imaging system.
  • [MeSH-minor] Aged. Aged, 80 and over. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Female. Humans. Keratosis, Actinic / drug therapy. Male. Middle Aged. Photosensitizing Agents / administration & dosage. Precancerous Conditions / drug therapy. Skin Neoplasms / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20806386.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


83. Ashton KJ, Carless MA, Griffiths LR: Cytogenetic alterations in nonmelanoma skin cancer: a review. Genes Chromosomes Cancer; 2005 Jul;43(3):239-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our purpose in this review is to discuss the cytogenetic findings on a number of nonmelanoma skin cancers, including squamous- and basal cell carcinomas, keratoacanthoma, squamous cell carcinoma in situ (Bowen's disease), and solar keratosis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15834942.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


84. Mauerer A, Betz RC, Pasternack SM, Landthaler M, Hafner C: Generalized solar lentigines in a patient with a history of radon exposure. Dermatology; 2010;221(3):206-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalized solar lentigines in a patient with a history of radon exposure.
  • The histopathology of the lesions was compatible with a diagnosis of solar lentigines (SLs) or flat seborrhoeic keratosis.
  • Genetic analysis identified a p.S249C FGFR3 hotspot mutation in 1 lesion, supporting the diagnosis of SLs.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Radon.
  • Hazardous Substances Data Bank. RADON, RADIOACTIVE .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664185.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3; Q74S4N8N1G / Radon
  •  go-up   go-down


85. Hoshina D, Akiyama M, Hata H, Aoyagi S, Sato-Matsumura KC, Shimizu H: Eccrine porocarcinoma and Bowen's disease arising in a seborrhoeic keratosis. Clin Exp Dermatol; 2007 Jan;32(1):54-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eccrine porocarcinoma and Bowen's disease arising in a seborrhoeic keratosis.
  • An association between seborrhoeic keratosis (SK) and malignant tumours is considered to be rare.
  • We observed a case of eccrine porocarcinoma and Bowen's disease (BD) occurring synchronously, forming one lesion in a SK on the abdomen.
  • It is controversial whether malignant neoplasms arising in SK occur only by chance or if pre-existing SK plays a role in pathogenesis.
  • This case suggests an implication of pre-existing SK in the subsequent development of both BD and eccrine porocarcinoma.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma / pathology. Eccrine Glands. Keratosis, Seborrheic / pathology. Skin Neoplasms / pathology. Sweat Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Dermatol. 2008 May;33(3):350-1 [18261140.001]
  • (PMID = 17004985.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Del Rosso JQ, Bikowski J: Trolamine-containing topical emulsion: clinical applications in dermatology. Cutis; 2008 Mar;81(3):209-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapeutic applications have included acute radiation dermatitis and postoperative wounds, and application after cryotherapy for actinic keratosis (AK).

  • Hazardous Substances Data Bank. TRIETHANOLAMINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18441842.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Emulsions; 0 / Ethanolamines; 9O3K93S3TK / triethanolamine
  • [Number-of-references] 15
  •  go-up   go-down


87. Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PC, Amerio P, Rønnevig J, Slade HB, Stockfleth E: Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol; 2007 Dec;157 Suppl 2:25-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.
  • OBJECTIVE: In this study the safety and efficacy of imiquimod 5% cream for the treatments of actinic keratoses in kidney, heart and liver transplant recipients is evaluated.
  • BACKGROUND: Growing populations of organ transplant recipients face increased risk of developing actinic keratosis (AK) and skin cancer secondary to continuous systemic immunosuppressive therapy.
  • Imiquimod 5% cream is an effective option for the treatment of AK, but the safety of topical immune stimulation in immunocompromised patients has not been widely evaluated.
  • CONCLUSIONS: Imiquimod appears to be a safe alternative for the treatment of multiple actinic keratoses in patients with solid organ transplants.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / drug therapy. Keratosis / drug therapy. Organ Transplantation. Skin Neoplasms / drug therapy


88. Kim JH, Bae HW, Lee KK, Kim TI, Kim EK: Seborrheic keratosis of the conjunctiva: a case report. Korean J Ophthalmol; 2009 Dec;23(4):306-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seborrheic keratosis of the conjunctiva: a case report.
  • Seborrheic keratosis is a benign epithelial neoplasia that occurs mainly in the skin of the eyelids and face.
  • We describe a case of seborrheic keratosis of the conjunctiva confirmed by histopathology.
  • Clinically, a diagnosis of conjunctival papilloma was made, and a mass excision was performed.
  • With the above findings, a diagnosis of conjunctival seborrheic keratosis was established.
  • The occurrence of seborrheic keratosis on the conjunctiva is rare.
  • In this case, seborrheic keratosis was confirmed by pathologic report despite its similar appearance with papilloma.
  • Seborrheic keratosis should be considered in the differential diagnosis of conjunctival lesions.
  • [MeSH-major] Conjunctival Diseases / diagnosis. Keratosis, Seborrheic / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Microscopy, Acoustic. Ophthalmologic Surgical Procedures / methods

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Ophthalmol. 2004 Jun;52(2):154-5 [15283223.001]
  • [Cites] Br J Ophthalmol. 1994 Apr;78(4):252-9 [8199108.001]
  • [Cites] Arch Dermatol Res. 1995;287(6):612-5 [7487151.001]
  • [Cites] Arch Soc Esp Oftalmol. 2006 Apr;81(4):217-9 [16688646.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • [Cites] Ophthalmology. 1999 Aug;106(8):1516-20 [10442897.001]
  • [Cites] Am J Dermatopathol. 1996 Jun;18(3):278-82 [8806962.001]
  • (PMID = 20046694.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2789958
  • [Keywords] NOTNLM ; Conjunctival mass / Papilloma / Seborrheic keratosis
  •  go-up   go-down


89. Kothiwale SV, Mathur S: Partial expression of Papillon-Lefèvre Syndrome. Indian J Dent Res; 2008 Jul-Sep;19(3):264-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is characterized by palmar plantar keratosis and severe early-onset periodontitis affecting both deciduous and permanent dentition.
  • The patient exhibited palmar plantar keratosis and an isolated, moderately deep periodontal pocket in the third quadrant.
  • [MeSH-major] Papillon-Lefevre Disease / diagnosis

  • Genetic Alliance. consumer health - Papillon Lefevre syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797107.001).
  • [ISSN] 0970-9290
  • [Journal-full-title] Indian journal of dental research : official publication of Indian Society for Dental Research
  • [ISO-abbreviation] Indian J Dent Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


90. Minagawa A, Koga H: Dermoscopy of pigmented poromas. Dermatology; 2010 Aug;221(1):78-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Pigmented poromas mimic a number of skin tumors, including pigmented basal cell carcinomas, seborrheic keratosis and malignant melanoma, because they present various clinical, dermoscopic and histopathological features.
  • [MeSH-major] Dermoscopy. Pigmentation Disorders / diagnosis. Poroma / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Keratosis, Seborrheic / diagnosis. Male. Melanoma / diagnosis. Middle Aged. Retrospective Studies. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20516657.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


91. Terada T: Pigmented Bowen disease arising in pigmented reticulated seborrheic keratosis. Int J Clin Oncol; 2010 Dec;15(6):608-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented Bowen disease arising in pigmented reticulated seborrheic keratosis.
  • A clinical diagnosis of basal cell carcinoma was made, and an excision with wide margins was performed.
  • The periphery of the tumor showed typical features of pigmented reticulated seborrheic keratosis.
  • This case suggests that pigmented Bowen disease can arise in pigmented reticulated seborrheic keratosis.
  • [MeSH-major] Bowen's Disease / etiology. Carcinoma, Basal Cell / complications. Keratosis, Seborrheic / complications. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dermatol Surg Oncol. 1988 Jul;14(7):765-9 [3292613.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):740-6 [12685552.001]
  • [Cites] J Cutan Pathol. 1989 Dec;16(6):348-52 [2533222.001]
  • [Cites] Mt Sinai J Med. 1974 Nov-Dec;41(6):792-801 [4279330.001]
  • [Cites] J Cutan Pathol. 1978 Dec;5(6):361-7 [154527.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):440-4 [2145328.001]
  • [Cites] Br J Dermatol. 1991 Mar;124(3):287-90 [1826848.001]
  • [Cites] Tohoku J Exp Med. 2005 Jul;206(3):271-5 [15942157.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):106-8 [16637805.001]
  • [Cites] Plast Reconstr Surg. 1998 Aug;102(2):453-5; discussion 456-8 [9703085.001]
  • (PMID = 20425131.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


92. Ko CJ, Iftner T, Barr RJ, Binder SW: Changes of epidermodysplasia verruciformis in benign skin lesions: the EV acanthoma. J Cutan Pathol; 2007 Jan;34(1):44-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These skin lesions included an intradermal nevus, a pigmented seborrheic keratosis, an isolated papule on the forearm, a perianal lesion, and an acantholytic acanthoma.
  • EV changes and EV-HPV can be found incidentally on biopsy in the absence of clinical EV; when such changes are the major histopathological finding in an isolated skin lesion, the lesion should be termed an EV acanthoma.
  • [MeSH-minor] Adult. Aged. Female. Humans. Keratosis, Seborrheic / pathology. Keratosis, Seborrheic / virology. Male. Middle Aged. Nevus / pathology. Nevus / virology. Papillomaviridae / classification. Papillomaviridae / isolation & purification


93. Zhang Y, Brodell RT, Mostow EN, Vinyard CJ, Marie H: In vivo skin elastography with high-definition optical videos. Skin Res Technol; 2009 Aug;15(3):271-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Continuous measurements of biomechanical properties of skin provide potentially valuable information to dermatologists for both clinical diagnosis and quantitative assessment of therapy.
  • In the three cases presented in this article (hypertrophic lichen planus, seborrheic keratosis and psoriasis vulgaris), abnormal tissues associated with the skin diseases were successfully identified in the elastograms.
  • CONCLUSIONS: Optical elastography is a promising imaging modality that is capable of capturing disease-induced property changes.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624423.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


94. Yao D, Alexander CL, Quinn JA, Chan WC, Wu H, Greenhalgh DA: Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity. J Cell Sci; 2008 May 15;121(Pt 10):1758-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RU486-treated HK1.Fos/Delta5Pten flx mice exhibited hyperplasia, hyperkeratosis and tumours that progressed to highly differentiated keratoacanthomas, rather than to carcinomas, owing to re-expression of high p53 and p21 WAF levels.
  • Despite elevated MAP kinase activity, cyclin D1 and cyclin E2 overexpression, and increased AKT activity that produced areas of highly proliferative papillomatous keratinocytes, increasing levels of GSK3beta inactivation induced a novel p53/p21 WAF expression profile, which subsequently halted proliferation and accelerated differentiation to give the hallmark keratosis of keratoacanthomas.
  • [MeSH-minor] Animals. Cyclin D. Cyclins / metabolism. Disease Progression. Mice. Mifepristone / pharmacology. Oncogene Protein v-akt / metabolism. Repressor Proteins / metabolism. Skin Neoplasms / metabolism


95. Stritt A, Merk HF, Braathen LR, von Felbert V: Photodynamic therapy in the treatment of actinic keratosis. Photochem Photobiol; 2008 Mar-Apr;84(2):388-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy in the treatment of actinic keratosis.
  • The efficacy of photodynamic therapy (PDT) with 5-aminolevulinate and methyl aminolevulinate in the treatment of actinic keratosis has been demonstrated in a large number of clinical studies over the last several years.
  • [MeSH-major] Keratosis / drug therapy. Photochemotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18221454.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


96. Morré DJ, Geilen CC, Welch AM, Morré DM: Response of carcinoma in situ (actinic keratosis) to green tea concentrate plus capsicum. J Diet Suppl; 2009;6(4):385-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of carcinoma in situ (actinic keratosis) to green tea concentrate plus capsicum.
  • A single case of carcinoma in situ (actinic keratosis) was treated topically with a patch consisting of an aqueous paste of a commercially available mixture (50:1) of green tea concentrate plus Capsicum (Capsol-T®) for approximately 14 days.
  • [MeSH-major] Camellia sinensis. Capsicum. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Keratosis, Actinic / drug therapy. Phytotherapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22435520.001).
  • [ISSN] 1939-022X
  • [Journal-full-title] Journal of dietary supplements
  • [ISO-abbreviation] J Diet Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts
  •  go-up   go-down


97. Green AC, McBride P: Squamous cell carcinoma of the skin (non-metastatic). BMJ Clin Evid; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: Does the use of sunscreen help prevent cutaneous squamous cell carcinoma and solar keratosis?

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cutan Med Surg. 2003 Jul-Aug;7(4):300-5 [12879331.001]
  • [Cites] Surg Gynecol Obstet. 1966 Feb;122(2):245-8 [5901291.001]
  • [Cites] Arch Surg. 1974 Jan;108(1):50-1 [4808574.001]
  • [Cites] Cancer. 1989 May 1;63(9):1863-71 [2702595.001]
  • [Cites] Am J Clin Oncol. 1991 Oct;14(5):383-6 [1951174.001]
  • [Cites] J Am Acad Dermatol. 1992 Mar;26(3 Pt 2):467-84 [1564155.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):574-7 [1463102.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):512-8 [8504041.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] Arch Dermatol. 1994 Aug;130(8):1018-21 [8053698.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Nov;113(5):589-96 [7478649.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):89-93 [10758309.001]
  • [Cites] Aust N Z J Surg. 2000 May;70(5):358-61 [10830600.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1061-9 [11240248.001]
  • [Cites] Arch Dermatol. 2003 Apr;139(4):451-5 [12707092.001]
  • [Cites] Plast Reconstr Surg. 2003 Jul;112(1):57-63 [12832877.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):124-30 [8606543.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1034-40 [8942434.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):628-34 [9610717.001]
  • [Cites] J Am Acad Dermatol. 1998 Jun;38(6 Pt 1):960-6 [9632005.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1304-9 [10433619.001]
  • [Cites] Head Neck. 1999 Sep;21(6):526-30 [10449668.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Med J Aust. 2006 Jan 2;184(1):6-10 [16398622.001]
  • [Cites] Prev Med. 2006 Mar;42(3):171-6 [16325898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2546-8 [17132769.001]
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1301-7 [17535230.001]
  • [Cites] Int Arch Occup Environ Health. 2009 Feb;82(3):357-63 [18649084.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2009 Apr;62(4):457-61 [18218349.001]
  • (PMID = 21733203.001).
  • [ISSN] 1752-8526
  • [Journal-full-title] BMJ clinical evidence
  • [ISO-abbreviation] BMJ Clin Evid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sunscreening Agents
  • [Other-IDs] NLM/ PMC2907617
  •  go-up   go-down


98. Koehler MJ, Elsner P, Kaatz M: Actinic damage and its treatments. G Ital Dermatol Venereol; 2010 Apr;145(2):175-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic damage and its treatments.
  • Over the last decades, there has been a dramatic increase of skin tumour incidence that results from actinic damage.
  • This review will focus on 1) the basic principles of actinic damage including carcinogenesis;.
  • [MeSH-minor] Humans. Keratosis, Actinic / etiology. Keratosis, Actinic / therapy. Skin Aging

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467391.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 75
  •  go-up   go-down


99. Augustine M, Jayaseelan E: Erythromelanosis follicularis faciei et colli: relationship with keratosis pilaris. Indian J Dermatol Venereol Leprol; 2008 Jan-Feb;74(1):47-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythromelanosis follicularis faciei et colli: relationship with keratosis pilaris.
  • The possibility of this condition being genetically related to keratosis pilaris as well as being a variant of keratosis rubra pilaris is also discussed.
  • [MeSH-major] Darier Disease / pathology. Erythema / pathology. Facial Dermatoses / pathology. Hyperpigmentation / pathology. Melanosis / pathology

  • Genetic Alliance. consumer health - Darier Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187825.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


100. Harris RB, Foote JA, Hakim IA, Bronson DL, Alberts DS: Fatty acid composition of red blood cell membranes and risk of squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev; 2005 Apr;14(4):906-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Logistic regression was used to estimate odds ratios (OR), adjusting for SCC risk factors (age, gender, actinic keratosis history, freckling, and tanning ability).
  • Increased levels of arachidonic acid in RBC membranes were associated with increased risk of SCC [odds ratio (OR), 1.08 per mg/100 mL change; 95% confidence interval (95% CI), 1.02-1.15] and this association remained when controls with actinic keratosis precursor lesions were excluded.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824162.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA027502-20; United States / NCI NIH HHS / CA / P01 CA027502-20; United States / NCI NIH HHS / CA / P01 CA27502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids
  •  go-up   go-down






Advertisement